Essity Prepares Sale of Consumer Tissue Business

Essity AB, a global hygiene and health company headquartered in Stockholm, Sweden, is reportedly preparing to initiate the sales process for its consumer tissue business. This potential divestment is expected to commence as soon as next month, according to individuals familiar with the matter. The move follows activist investor Cevian Capital's acquisition of a minority stake in Essity, a development that may have influenced the company's strategic considerations. Essity's consumer tissue operations encompass a range of products, including toilet paper, paper towels, and facial tissues, which are marketed under various brands in different regions. The company's decision to explore a sale of this segment suggests a strategic shift, potentially focusing on other areas of its business, such as professional hygiene or medical solutions. Cevian Capital, known for its activist investment approach, typically aims to drive operational improvements and strategic changes within the companies it invests in. Their involvement with Essity could signal a push for greater efficiency, profitability, or a realignment of the company's portfolio. Essity operates in numerous countries worldwide, with its consumer tissue products being a significant part of its historical business. The company's broader portfolio includes brands like Tork in professional hygiene and Leukoplast and Cutimed in medical solutions. The potential sale of the consumer tissue division could involve either a full divestiture through a sale to another company or a public listing of the business unit as a separate entity. The specifics of the transaction, including the valuation and the timeline for completion, remain subject to market conditions and negotiations. Essity's management has not yet officially commented on the reported plans, but market analysts are closely watching for further developments. The consumer tissue market is characterized by intense competition and evolving consumer preferences, with increasing emphasis on sustainability and product innovation. A sale could allow Essity to streamline its operations and allocate resources more effectively towards its growth areas. The company's financial performance and market position in the consumer tissue segment would be key factors in determining the attractiveness of a potential sale or listing. Essity's global presence means that any divestment would likely have implications for its operations and workforce across various international markets. The company's commitment to sustainability, a growing concern for consumers and investors alike, will also be a consideration in the sale process, with potential buyers expected to align with Essity's environmental, social, and governance (ESG) objectives. The timing of the sales process, set to begin as early as next month, indicates a degree of urgency or a well-defined strategic window for Essity to execute its plans. The involvement of investment banks or advisors in managing the sale process is also anticipated, though not yet confirmed. The outcome of this potential divestment could reshape Essity's business structure and its competitive standing in the global hygiene and health industry.